...
首页> 外文期刊>Cell death & disease. >Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis
【24h】

Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis

机译:药理LRH-1 / NR5A2抑制限制巨噬细胞和相关实验性肝炎中的促炎细胞因子产生

获取原文
           

摘要

Liver receptor homolog-1 (LRH-1, Nr5a2) is an orphan nuclear receptor mainly expressed in tissues of endodermal origin, where its physiological role has been extensively studied. LRH-1 has been implicated in liver cell differentiation and proliferation, as well as glucose, lipid, and bile acid metabolism. In addition, increasing evidence highlights its role in immunoregulatory processes via glucocorticoid synthesis in the intestinal epithelium. Although the direct function of LRH-1 in immune cells is fairly elucidated, a role of LRH-1 in the regulation of macrophage differentiation has been recently reported. In this study, we aimed to investigate the role of LRH-1 in the regulation of pro-inflammatory cytokine production in macrophages. Our data demonstrate that pharmacological inhibition, along with LRH-1 knockdown, significantly reduced the lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines in the macrophage line RAW 264.7 cells, as well as in primary murine macrophages. This inhibitory effect was found to be independent of defects of LRH-1-regulated cell proliferation or toxic effects of the LRH-1 inhibitors. In contrast, LRH-1 inhibition reduced the mitochondrial ATP production and metabolism of macrophages through downregulation of the LRH-1 targets glucokinase and glutminase-2, and thus impairing the LPS-induced macrophage activation. Interestingly, in vivo pharmacological inhibition of LRH-1 also resulted in reduced tumor necrosis factor (TNF) production and associated decreased liver damage in a macrophage- and TNF-dependent mouse model of hepatitis. Noteworthy, despite hepatocytes expressing high levels of LRH-1, pharmacological inhibition of LRH-1 per se did not cause any obvious liver damage. Therefore, this study proposes LRH-1 as an emerging therapeutic target in the treatment of inflammatory disorders, especially where macrophages and cytokines critically decide the extent of inflammation.
机译:肝受体同源物 - 1(LRH-1,NR5A2)是主要在内胚层起源组织中表达的孤儿核受体,其生理作用已被广泛研究。 LRH-1已涉及肝细胞分化和增殖,以及葡萄糖,脂质和胆汁酸代谢。此外,越来越多的证据突出了通过肠上皮中的糖皮质激素合成的免疫调节过程中的作用。尽管LRH-1在免疫细胞中的直接功能相当阐明,但最近已经报道了LRH-1在调节巨噬细胞分化中的作用。在这项研究中,我们旨在探讨LRH-1在巨噬细胞中促炎细胞因子产生调节中的作用。我们的数据表明,药理学抑制以及LRH-1敲低,显着降低了脂多糖(LPS) - 诱导巨噬细胞生产中的促炎细胞因子的产生,以及初级鼠巨噬细胞。发现这种抑制作用与LRH-1抑制剂的LRH-1调节细胞增殖或毒性作用无关。相比之下,LRH-1抑制通过LRH-1靶向葡萄糖蛋白酶和谷氨酸酶-2的下调降低了巨噬细胞的线粒体ATP生产和代谢,从而损害了LPS诱导的巨噬细胞活化。有趣的是,在体内药理学抑制LRH-1的情况下也导致肿瘤坏死因子(TNF)产生和相关的肝炎的巨噬细胞和TNF依赖性小鼠模型中的肝脏损伤减少。值得注意的是,尽管表达了高水平的LRH-1,但LRH-1本身的药理抑制不会引起任何明显的肝损伤。因此,本研究提出了LRH-1作为治疗炎症障碍的新出现治疗靶标,特别是在巨噬细胞和细胞因子重视炎症程度的情况下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号